Daniel Lynch, Director at SpringWorks Therapeutics, Inc. (SWTX), sold 95,200 shares at $61.24 ($5.7M) on 2025-02-20, disclosed to the SEC on 2025-02-24.
Scheduled sale ($5.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.14 | 44,018 | $2.6M | 46.2% |
| 2 | $60.14 | 44,018 | $2.6M | 46.2% |
| 3 | $61.24 | 3,582 | $219K | 3.8% |
| 4 | $61.24 | 3,582 | $219K | 3.8% |
| Total | $60.22 avg | 95,200 | $5.7M | 100% |
| Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2018-02-14 | $2.6M | — | Filing → |
| BPMC | SELL | 2017-11-17 | $420K | — | Filing → |